RxDoctor Payments Data

Frances Long, MD

Internal Medicine · Atlanta, GANPI 1194778316

Payments from drug & device makers

$2,221in general payments, 2019–2025

Across 118 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$376
  • Lilly USA, LLC$248
  • Currax Pharmaceuticals LLC$195
  • Novo Nordisk$189
  • Pfizer$181
  • Abbott$178
  • plus $854 from 16 others

What the payments were for

  • Food & beverage$2,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,221 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$135,634
Medicare patients
181
Services billed
2,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate13$15,958
MounjaroTirzepatide13$13,894
OzempicSemaglutide12$11,435
Estradiol82$3,038
SynthroidLevothyroxine Sodium28$2,706
Potassium Chloride15$1,839
Levothyroxine Sodium217$1,592
Rosuvastatin Calcium190$1,539
Ezetimibe45$1,532
Estradiol (Twice Weekly)Estradiol16$1,222
Wixela InhubFluticasone Propion/Salmeterol11$1,199
Liothyronine Sodium22$1,159
Atorvastatin Calcium127$1,098
Amlodipine Besylate137$758
Losartan Potassium65$643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$86$15,95813 claims
Lilly USA, LLCMounjaro$248$13,89413 claims
Novo NordiskOzempic$189$11,43512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →